Manufacturing Daily Summary
Manufacturing Daily Summary: What Happened on November 18, 2026
mAbxience backs OncoPrecision and will make material for its cancer candidate
Other manufacturing work spans engineered TIL production, rapid sterility testing for cell therapies and a biodegradable purification resin evaluated in four applications.
Today in brief
mAbxience invested in OncoPrecision and agreed to develop ONC001’s antibody component and make GMP-grade material for a planned Phase 1 trial.1
Separate teams are testing automated production of engineered TILs, a phased sterility-testing route for cell therapies and a biodegradable resin across four purification applications.234
mAbxience backs OncoPrecision’s ONC001 development
mAbxience made a strategic investment in OncoPrecision and agreed to develop and manufacture material for ONC001, a preclinical antibody-drug conjugate.1 The work covers the antibody component, from cell-line work through process and analytical development, followed by GMP-grade production for a planned Phase 1 trial.1
The companies describe ONC001 as a CD64-directed candidate targeting leukemic monocytes and tumor-associated macrophages, with monocytic acute myeloid leukemia and chronic myelomonocytic leukemia as lead indications.1 mAbxience CEO Jurgen Van Broeck will join OncoPrecision’s board as an observer.1
Also worth knowing
-
Terumo BCT, TrAMPoline Pharma and the University of Colorado are using the Quantum Flex Cell Expansion System to automate production of genetically engineered tumor-infiltrating lymphocytes. Early work will compare automated expansion with the current method.2
-
Athena Stathoulis and colleagues proposed a three-stage alternative sterility-testing pathway for cell therapies, combining parallel testing and conditional release with post-infusion compendial testing as a safeguard.3
-
B
Medium Well and its partners evaluated biodegradable BioResin in four protein-purification applications. The resin maintained stable performance through as many as 100 cleaning cycles.4